Business
Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz(R)-PDT
WOBURN, MA / ACCESSWIRE / June 1, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the
About this update from Biofrontera Inc.
[{"type":"text","content":"WOBURN, MA / ACCESSWIRE / June 1, 2023 / Biofrontera Inc. (Nasdaq:BFRI) (\"Biofrontera\" or the \"Company\"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces it has engaged a contract manufacturer to develop a new, low-cost portable photodynamic therapy (PDT) lamp for use with Ameluz® (Ameluz®-PDT). Prior to this engagement, Biofrontera acquired one issued U.S. patent and all rights from one of two inventors on another issued U.S. patent related to a portable red-light lamp for use in PDT. The inventors of the patents are working with Biofrontera on the lamp development.Biofrontera will make regulatory and commercial milestone payments to the patent holders, and will also pay royalties on future net sales of products utilizing the acquired patents.\"Our flagship product, Ameluz, and the Rhodo-LED® lamps are gaining significant sales traction among dermatologists for the treatment of actinic keratosis (AK). These two patents broaden our PDT intellectual property and allow for the development of a potential third option in our BF-RhodoLED series of lamps that opens additional commercial opportunity,\" said Hermann Luebbert, Chairman and Chief Executive Officer of Biofrontera Inc.\"A low-cost, portable lamp, if approved by the FDA, is particularly well-suited for clinicians new to PDT or those with limited office space. The lamp will be designed with a small footprint to enable easy storage and portability to allow clinicians to bring the lamp to patients, for instance in care facilities. A portable lamp is also easier for sales reps to offer live demonstrations at physician offices,\" added Mr. Luebbert.Development of a prototype portable PDT lamp is expected to begin later this month.About Actinic KeratosisActinic keratosis (AK) is the most common pre-cancerous skin lesion caused by chronic sun exposure that may, if left untreated, develop into life-threatening skin cancer called squamous cell carcinoma. AKs typically appear on sun-exposed areas such as the face, bald scalp, arms or the back of the hands. According to the Skin Cancer Foundation, in the U.S. AK affected approximately 58 million people in 2020 and an estimated 13 million AK treatments were performed.About Biofrontera Inc.Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pr...